We aimed to evaluate and compare the efficacy and safety of three antidiabetic drug classes—SGLT2 inhibitors, GLP-1 receptor agonists, and sulfonylureas—in patients with type 2 diabetes mellitus (T2DM) complicated by heart failure (HF). This evidence concerns the gene SLC5A2 and heart failure.